

Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

Submission date 09/05/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 16/05/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 18/02/2008	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ricardo Agurto-Rivera

Contact details
Exequiel Fernández n° 920
Casa F
Ñuñoa
Santiago
Chile
+56 8 5021968
ricardo_agurto@yahoo.com

Additional identifiers

Study information

Scientific Title

Study objectives

TTT plus intravitreal triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Age-Related Macular Degeneration (ARMD) not available for current therapies

Interventions

Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreal Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Triamcinolone

Primary outcome(s)

Preservation of visual acuity

Key secondary outcome(s)

Closure of CNV, OCT characteristics

Completion date

28/02/2006

Eligibility**Key inclusion criteria**

Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV

Date of first enrolment

01/02/2004

Date of final enrolment

28/02/2006

Locations**Countries of recruitment**

Chile

Mexico

Study participating centre

Exequiel Fernández n° 920

Santiago

Chile

Sponsor information**Organisation**

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

ROR

<https://ror.org/03sgfhr82>

Funder(s)

Funder type

Charity

Funder Name

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	25/11/2005		Yes	No